GLOBAL BLOOD THERAPEUTICS IN (GBT)
US37890U1088 - Common Stock
| MRQ (2022-6-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 261.15M | 684.72M | 494.80M | 302.20M | 275.40M | |||
| Marketable Securities | 256.01M | 0.00 | 66.10M | 307.70M | 202.20M | |||
| Receivables | 29.77M | 28.80M | 17.50M | 2.60M | N/A | |||
| Inventories | 65.82M | 58.20M | 40.20M | 1.30M | N/A | |||
| Other Current Assets | 27.27M | 30.25M | 13.50M | 14.10M | 8.20M | |||
| Total Current Assets | 640.01M | 801.97M | 632.20M | 628.00M | 485.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 78.92M | 82.93M | 88.60M | 79.90M | 15.00M | |||
| Investments And Advances | 146.86M | 50.06M | 0.00 | 85.00M | 114.30M | |||
| Other Non-Current Assets | 4.65M | 4.25M | 3.20M | 3.20M | 2.60M | |||
| Total Non-Current Assets | 230.43M | 137.24M | 91.80M | 168.10M | 131.80M | |||
| TOTAL ASSETS | 870.44M | 939.21M | 724.00M | 796.10M | 617.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 84.57M | 72.68M | 60.00M | 60.80M | 26.80M | |||
| Accounts Payable | 8.26M | 15.10M | 19.10M | 10.60M | 6.00M | |||
| Other Current Liabilities | 260.00K | 222.00K | N/A | 0.00 | 900.00K | |||
| Total Current Liabilities | 93.09M | 88.00M | 79.00M | 71.50M | 33.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 581.95M | 580.44M | 148.80M | 73.60M | 0.00 | |||
| Other Non-Current Liabilities | 77.05M | 74.36M | 80.00M | 72.40M | 11.10M | |||
| Total Non-Current Liabilities | 658.99M | 654.80M | 228.80M | 145.90M | 11.00M | |||
| TOTAL LIABILITIES | 752.08M | 742.80M | 307.80M | 217.40M | 44.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.45B | -1.29B | -986.50M | -738.90M | -472.20M | |||
| Additional Paid In Capital | 1.58B | 1.49B | 1.40B | 1.32B | 1.04B | |||
| Common Shares | 67.00K | 65.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -3.97M | 100.00K | 300.00K | 800.00K | 0.00 | |||
| Shares Outstanding | 67.27M | 64.64M | 61.90M | 60.60M | 55.60M | |||
| Tangible Book Value per Share | 1.76 | 3.04 | 6.72 | 9.55 | 10.30 | |||
| Total Shareholders' Equity | 118.36M | 196.41M | 416.20M | 578.70M | 572.80M | |||
| TOTAL LIABILITIES AND EQUITY | 870.44M | 939.21M | 724.00M | 796.10M | 617.60M | |||
| Statistics | ||||||||
| Debt/Equity | 4.92 | 2.96 | 0.36 | 0.13 | N/A | |||
| Current Ratio | 6.88 | 9.11 | 8.00 | 8.78 | 14.37 | |||
| Return On Assets (ROA) | -37.05% | -32.27% | -34.20% | -33.51% | -28.21% | |||
| Return On Equity (ROE) | -272.44% | -154.32% | -59.49% | -46.10% | -30.41% | |||
All data in USD